Program
CIT-013
A development code. Also written as “CIT-013 high dose”, “CIT-013 medium dose” and “CIT-013 low dose”.
Its studies are mostly in Arthritis, Rheumatoid · Hidradenitis Suppurativa, led by Citryll BV.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Citryll BV | 31 open or running | phase 2since Aug 16, 2024 | Aug 16, 2024 | Apr 2027phase 2 · NCT06993233 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 16, 2024First study: phase 2 study in Arthritis, RheumatoidFirst studyNCT06567470 · 96 enrolled · Belgium, Germany, Netherlands and more
- May 19, 2025Phase 2 study in Hidradenitis SuppurativaNCT06993233 · 108 enrolled · Canada, Germany, Netherlands and more
- Mar 24, 2026Phase 1 study in Healthy AdultNCT07499908 · 10 enrolled · Netherlands
Ahead
- Apr 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT06993233
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07499908Healthy Adult · Netherlands | 1 | Completed | Aug 10, 2026 | 10 |
| NCT06993233Hidradenitis Suppurativa · Canada, Germany, Netherlands and more | 2 | Active, not recruiting | Apr 2027 | 108 |
| NCT06567470Arthritis, Rheumatoid · Belgium, Germany, Netherlands and more | 2 | Completed | Jul 2, 2026 | 96 |
How it is read
Names in the registry
- “CIT-013 high dose”, 3 entries
- “CIT-013 medium dose”, 2 entries
- “CIT-013 low dose”, 1 entry
Codes read as this program: CIT013.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 1 study
- Hidradenitis Suppurativa, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.